.

Make Better Decisions

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cantor Fitzgerald
Accenture
Boehringer Ingelheim
Cipla
US Department of Justice
Fuji
Medtronic
Farmers Insurance
Dow
Colorcon

Generated: November 24, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,530,694

« Back to Dashboard

Which drugs does patent 8,530,694 protect, and when does it expire?


Patent 8,530,694 protects NINLARO and is included in one NDA.

This patent has forty-nine patent family members in thirty-two countries.

Summary for Patent: 8,530,694

Title:Proteasome inhibitors
Abstract: The present invention provides novel compounds useful as proteasome inhibitors. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases.
Inventor(s): Olhava; Edward J. (Newton, MA), Danca; Mihaela Diana (Mendham, NJ)
Assignee: Millennium Pharmaceuticals, Inc. (Cambridge, MA)
Application Number:13/209,511
Patent Claim Types:
see list of patent claims
Compound; Composition; Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Millennium Pharms
NINLARO
ixazomib citrate
CAPSULE;ORAL208462-001Nov 20, 2015RXYesNo► Subscribe► SubscribeYY METHOD FOR TREATING CANCER, INCLUDING MULTIPLE MYELOMA
Millennium Pharms
NINLARO
ixazomib citrate
CAPSULE;ORAL208462-002Nov 20, 2015RXYesNo► Subscribe► SubscribeYY METHOD FOR TREATING CANCER, INCLUDING MULTIPLE MYELOMA
Millennium Pharms
NINLARO
ixazomib citrate
CAPSULE;ORAL208462-003Nov 20, 2015RXYesYes► Subscribe► SubscribeYY METHOD FOR TREATING CANCER, INCLUDING MULTIPLE MYELOMA
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 8,530,694

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,442,830Proteasome inhibitors► Subscribe
8,772,536Proteasome inhibitors► Subscribe
8,871,745Proteasome inhibitors► Subscribe
8,003,819Proteasome inhibitors► Subscribe
7,687,662Proteasome inhibitors► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 8,530,694

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Tunisia2010000060► Subscribe
Slovenia2178888► Subscribe
Singapore10201508712Q► Subscribe
Serbia52435► Subscribe
Portugal2178888► Subscribe
Poland2178888► Subscribe
South Korea20140042932► Subscribe
South Korea101474831► Subscribe
South Korea20100059811► Subscribe
Japan5261488► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Queensland Health
Harvard Business School
Boehringer Ingelheim
Mallinckrodt
Dow
Julphar
Daiichi Sankyo
Fuji
McKesson
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot